C4 therapeutics announces fda clearance of investigational new drug application for cft7455, an orally bioavailable monodac for hematologic malignancies

– phase 1/2 clinical study of cft7455 expected to initiate in 1h 2021 – – phase 1/2 clinical study of cft7455 expected to initiate in 1h 2021 –

CCCC Ratings Summary

CCCC Quant Ranking